RhD refers to a protein found on the surface of red blood cells. About 85% of people carry this protein and are considered “Rh positive,” while the remaining 15% lack it and are “Rh negative.” In pregnancy, RhD becomes important when an Rh-negative mother carries an Rh-positive baby, because her immune system can treat the baby’s blood cells as foreign invaders. This immune reaction can cause serious complications, but modern prevention makes it highly manageable.
How RhD Incompatibility Happens
You inherit your Rh status from your parents. If you’re Rh-negative and your partner is Rh-positive, your baby may be Rh-positive. During pregnancy, your blood and your baby’s blood don’t normally mix. But small amounts of fetal blood can cross into your circulation during labor and delivery, or during events like bleeding, amniocentesis, abdominal trauma, or procedures to turn a breech baby.
When your immune system encounters those Rh-positive blood cells for the first time, it produces antibodies against the RhD protein. This process is called sensitization. It usually doesn’t cause problems for the first baby, because the immune response takes time to build. The real danger comes in a future pregnancy with another Rh-positive baby. Your immune system now recognizes the RhD protein immediately and launches a much faster, stronger attack, sending antibodies across the placenta to destroy the baby’s red blood cells.
Sensitization can also happen after a miscarriage, ectopic pregnancy, or induced abortion, since even these early pregnancies can involve enough fetal blood to trigger an immune response.
What Happens to the Baby
When maternal antibodies destroy fetal red blood cells, the result is hemolytic disease of the fetus and newborn (HDFN). The severity ranges from mild to life-threatening, depending on how strong the mother’s antibody response is.
The first problem is anemia. As the baby loses red blood cells faster than it can replace them, oxygen delivery throughout the body drops. In severe cases, the baby’s heart begins to fail under the strain, leading to a condition called hydrops fetalis, where fluid accumulates abnormally in multiple areas of the body. On ultrasound, this appears as swelling around the skull, chest, and abdomen, with fluid collecting in body cavities. It can develop as early as 20 weeks of pregnancy.
After birth, the concern shifts to jaundice. The rapid breakdown of red blood cells floods the newborn’s system with bilirubin, a yellow waste product the liver processes. A newborn’s liver is still immature and can be overwhelmed by the excess. If bilirubin levels climb high enough, the substance can cross into the brain and cause permanent neurological damage, a condition called kernicterus.
Who Is at Risk
Only Rh-negative mothers carrying Rh-positive babies face this issue. The prevalence of Rh-negative blood varies dramatically by ethnicity. In the United States, about 15% of the population is Rh-negative. In Britain, it’s around 17%. Among Basque populations and certain Moroccan communities, rates reach as high as 29%. In contrast, Rh-negative blood is far less common in East Asia, with less than 1% of people in China, Japan, and Indonesia testing negative. Rates in India range from roughly 1% to 8%, and in parts of Africa they fall between 1% and 7%.
Your blood type is tested at your first prenatal visit, so you’ll know early whether this applies to you.
How Doctors Monitor for Problems
If you’re Rh-negative, your blood will be screened for anti-RhD antibodies at the start of pregnancy and again around 28 weeks. If antibodies are detected, monitoring becomes more intensive.
The primary tool for checking whether the baby is becoming anemic is a specialized ultrasound that measures blood flow speed in an artery in the baby’s brain. When a baby is anemic, its blood becomes thinner and flows faster. A reading above 1.5 times the expected value for the baby’s gestational age signals moderate to severe anemia and typically triggers further intervention. This test avoids the need for invasive procedures in about 70% of cases.
A newer option is non-invasive prenatal testing (NIPT) using a simple blood draw from the mother. Fragments of fetal DNA circulate in the mother’s bloodstream, and labs can analyze these to determine whether the baby is Rh-positive or Rh-negative. When using cell-free DNA from maternal plasma, accuracy reaches about 96.5%. This test is particularly useful because if the baby turns out to be Rh-negative, no further Rh-related precautions are needed at all.
Prevention With Rh Immunoglobulin
The cornerstone of prevention is Rh immunoglobulin, commonly known by the brand name RhoGAM. This injection contains antibodies that neutralize any fetal Rh-positive blood cells in your system before your immune system has a chance to react and form its own antibodies. It works only as prevention. Once you’ve already been sensitized, it cannot reverse the process.
The standard schedule involves an injection at 28 weeks of pregnancy, since small amounts of fetal blood can begin mixing with yours in the final trimester. A second dose is given within 72 hours after delivery if the baby is confirmed Rh-positive. Some protocols also include a dose at 34 weeks. The timing matters: the injection should be given as soon as practical within 72 hours of any sensitizing event. If delayed beyond that window, it can still be administered up to 10 days later, though with reduced effectiveness.
You’ll also receive the injection after any event that could cause fetal-maternal blood mixing: miscarriage, ectopic pregnancy, amniocentesis, chorionic villus sampling, significant bleeding, abdominal trauma, or a procedure to turn a breech baby. For events in the first 12 weeks, a smaller dose is used. Beyond 12 weeks, a full dose is given.
Treatment When Sensitization Has Already Occurred
If you’ve already developed antibodies from a previous pregnancy or blood exposure, prevention is no longer an option. The focus shifts to close monitoring and, if needed, direct treatment of the baby.
For severe fetal anemia, the primary intervention is an intrauterine transfusion, where Rh-negative blood is delivered directly to the baby through a needle guided by ultrasound. This procedure has a fetal survival rate of about 90%, rising to nearly 96% for babies without hydrops. For babies who have already developed hydrops, survival drops to around 61%. The risk of complications from the procedure itself is about 4.5% per transfusion, with a fetal loss rate of 1.6% per procedure.
After birth, affected babies often need phototherapy (light treatment) to bring down bilirubin levels. In more severe cases, an exchange transfusion may be necessary, where a portion of the baby’s blood is gradually replaced with fresh blood to remove both the excess bilirubin and the attacking antibodies. About 30% of babies who received intrauterine transfusions develop late anemia in the weeks after birth and need additional blood transfusions during that period.
What This Means for Future Pregnancies
If you’re Rh-negative and have never been sensitized, receiving Rh immunoglobulin on schedule during each pregnancy keeps the risk extremely low. The introduction of routine prophylaxis has made severe HDFN rare in countries where it’s widely available.
If you have been sensitized, every subsequent pregnancy with an Rh-positive baby carries risk, and the immune response typically grows stronger with each exposure. Early and consistent prenatal care allows doctors to catch problems before they become dangerous. Non-invasive fetal RhD testing can determine early on whether the baby even carries the Rh protein, potentially sparing you months of intensive monitoring if the baby is Rh-negative.